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1. Introduction 
Tumors are heterogeneous in their cellular morphology, proliferation rate, differentiation 
grade, genetic lesions, and therapeutic response. The cellular and molecular mechanisms 
that cause tumor heterogeneity are largely unknown. Growing evidence suggests that 
tumors are organized in a hierarchy of heterogeneous cell populations and are made and 
maintained from a small population of stem/stem-like cells called cancer stem cells (CSCs). 
CSCs are defined on the basis of characteristics such as high tumorigenicity, self-renewal, 
and differentiation that contribute to heterogeneity. Cancer recurrence is thought to be due 
to CSCs that are resistant to chemotherapy and radiation. 
Dick and his coworkers first reported that all cancer phenotypes present in acute myeloid 
leukemia (AML) were derived from a few rare populations (0.1–1% of total cells) (Bonnet & 
Dick, 1997). These leukemic stem cells were isolated from the peripheral blood of AML 
patients by the surface markers CD34+/CD38-, which are similar to those in normal 
hematopoietic stem cells. These CSCs had a much higher rate of self-renewal than normal 
stem cells and recapitulated the morphological features of the original malignancy when 
engrafted in immunodeficient mice. CSCs are thought to have the ability to self-renew and 
to produce heterogeneous tumors. 
This discovery paved the way for the study of CSCs in solid tumors. Based on a similar 
approach of combined flow cytometry and xenotransplantation, many researchers 
attempted to isolate CSCs from other tumors. Since the isolation of rare CSCs is a crucial 
step, the method of CSC isolation using flow cytometry has been improved by using surface 
markers, side populations, and the ALDEFLUOR assay, as described below. Thus far, CSCs 
have been found in various solid tumors, including breast, brain, colon, pancreas, prostate, 
and ovarian tumors (Collins et al., 2005; Curley et al., 2009; Dalerba et al., 2007; Ponti et al., 
2005; Singh et al., 2004).  
It is still unclear how CSCs are generated. It has been speculated that normal stem cells in 
various tissues are malignantly transformed by multiple steps such as genetic and 
epigenetic mutations (Visvader & Lindeman, 2008). A recent study suggests that the 
dedifferentiation of transformed malignant cells results in the production of CSCs (Gupta et 
al., 2011). Although there is still a lot of controversy regarding CSCs, a CSC model might 
provide a potential screening strategy for drug discovery (Gupta et al., 2009). Given the 
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variation of CSCs both in primary specimens and established cancer cell lines, it is essential 
to characterize CSCs and to optimize the isolation protocol.  
This review focuses on the current protocols to identify and characterize CSCs by flow 
cytometry. In particular, the isolation of CSCs from established breast cancer cell lines is 
used as a simple model. These protocols would provide new insights into the targeting of 
CSCs and the implications for cancer therapy. 
2. Sphere formation 
Normal stem cells have the ability to proliferate in suspension as non-adherent spheres. 
Neural stem cells and their derived progenitor cells can be enriched and expanded in vitro 
by their ability to form floating aggregates called neurospheres (Reynolds & Weiss, 1992). 
These non-adherent spheres were enriched in stem/progenitor cells and were able to 
differentiate into neurons and glia. In these spheres, between 4% and 20% of the cells were 
stem cells whereas the other cells represented progenitor cells in different phases of 
differentiation (Weiss et al., 1996), suggesting that stem cells had been successfully enriched. 
The markers and receptors that regulate neural stem cell growth have been identified using 
this cell culture system (Hiramoto et al., 2007; Holmberg et al., 2005; Nagato et al., 
2005).These non-adherent culture conditions were also adapted to other normal stem cells. 
Mammary stem cells that are grown in suspension form mammospheres, which are the 
equivalent of neurospheres (Dontu et al., 2003).  
      
                                   (A)                                                                                                    (B) 
Fig. 1. Mammosphere culture in established breast cancer cell lines (A) ER-positive (MCF-7, 
HCC1806) and ER-negative (MDA-MB-231, BT20) breast cancer cell lines were seeded in 
stem cell medium in ultra-low attachment dishes (Corning). After 7 days, mammospheres 
were observed in MCF-7, HCC1806, and BT20 cells. MDA-MB-231 cells produced loosely 
adherent cell clumps. (B) Expression of stemness markers in sphere culture from MCF-7 and 
MDA-MB-231 cells 
Subsequently, the sphere culture technique was applied to grow stem cell populations from 
a variety of clinical cancer samples or cancer cell lines, such as brain cancers (Galli et al., 
2004; Singh et al., 2003, 2004). We also applied this approach to form non-adherent 
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mammospheres using established human cancer cell lines, such as MCF-7 (Hirata et al., 
2010). As shown in Fig. 1A, both estrogen receptor (ER)-positive and ER-negative breast 
cancer cell lines can grow as mammospheres in stem cell medium without serum that is 
supplemented with growth factors such as basic FGF and N2.Compared with adherent cells, 
sphere cells from MCF-7 and MDA-MB-231 cells exhibited higher expression of stemness 
markers such as Nanog, Sox2, and c-Myc, suggesting that they have self-renewal properties 
(Fig. 1B). In addition, sphere cells have shown high tumorigenicity when injected in 
immunodeficient mice (Fillmore & Kuperwasser, 2008). 
Thus, the sphere assay might represent a potentially valid and useful technique for 
enrichment of CSCs from clinical specimens or cell lines. However, the stem cell population 
cannot be purified completely by the sphere technique because CSCs from primary tumors 
are highly variable (Visvader & Lindeman, 2008) and it is possible that the stem cell 
population is contaminated with more differentiated cells. Therefore, further purification of 
CSCs by flow cytometry would be required for CSC characterization.  
3. Surface markers 
Expression of cell surface markers has been widely used to isolate normal stem cells and the 
choice of markers varies among tissues and species. As shown in Table 1, CSCs have been 
isolated by various markers from many types of cancers and these cell surface markers are 
similar to their normal counterparts. 
Tumor type Surface markers References Year 
Acute myeloid leukemia CD34+/CD38- Bonnet & Dick 1997 
Breast CD44+/CD24- Al-Hajj et al. 2003 
Brain CD133+ Singh et al. 2003 
Prostate CD133+ Miki et al. 2004 
Colon CD133+ O’Brien et al. 2005 
Melanoma CD20+ Fang et al. 2005 
Head and neck CD44+ Prince et al. 2007 
Pancreas CD133+/CXCR4+ Hermann et al. 2007 
Ovary CD44+/CD24+/ESA+ Zhang et al. 2008 
Glioblastoma CD49f+ Lathia et al. 2010 
Table 1. Distinct surface markers for isolation of CSCs from different cancer types 
3.1 CD34
+
/CD38
-
 
As described in the Introduction, CD34+/CD38- cell population has been identified as a cell 
surface marker on leukemic CSCs. This CD34+/CD38- cell population had the capacity to 
initiate leukemia in NOD-SCID mice when compared with CD34- and CD34+/CD38+ cell 
population (Bonnet & Dick, 1997). Although the identification of leukemic CSCs was a major 
advancement in stem cell field, this subpopulation is still considered heterogeneous (Sarry 
et al., 2011). A strict definition of leukemic CSCs is necessary to further target these cells.  
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3.2 CD44
+
/CD24
-
 
Al-Hajj et al. found CSCs in human solid tumors by using CD44+CD24-/low in breast cancer 
cells (Al-Hajj et al., 2003). As few as 200 cells from this subpopulation were able to form 
tumors when injected into NOD/SCID mice, whereas tens of thousands of other cells did 
not form tumors (Al- Hajj et al., 2003). The tumors from this subpopulation recapitulated the 
phenotypic heterogeneity of the initial tumor, containing a minority of CD44+CD24-/low cells. 
The CD44+CD24-/low phenotype has been used to identify and isolate CSCs from breast 
cancer specimens after in vitro expansion (Ponti et al., 2005) and from breast cancer cell lines 
(Fillmore & Kuperwasser, 2008). In addition to breast cancer, CSCs in ovarian cancer cells 
have been isolated by using CD44+/CD24- (Zhang et al., 2008). 
Cancer cell lines that are enriched in CD44+CD24-/low cells are not more tumorigenic than 
cell lines that contain only 5% of cells with the same phenotype (Fillmore & Kuperwasser, 
2008), suggesting that CD44+/CD24-/low cells are heterogeneous and only a subgroup within 
the CD44+CD24-/low cells is self-renewing.  
3.3 CD133 
CD133, also known as PROML1 or prominin, is a transmembrane glycoprotein that was 
identified in mouse neuroepithelial stem cells (Weigmann et al., 1997) and human 
hematopoietic stem cells (Miraglia et al., 1997). CD133 was also found on progenitor cells in 
endothelial cells (Peichev et al., 2000), lymphangiogenic cells (Salven et al., 2003) and 
myoangiogenic cells (Shmelkov et al., 2005). Although its biological function is still unclear, 
CD133 has been recognized as a putative CSC marker for brain, colon, and prostate cancers 
(Miki et al., 2007; O'Brien et al., 2007; Ricci-Vitiani et al., 2007; Richardson et al., 2004; Singh 
et al., 2004). In addition, CD133+CXCR4+ CSCs were found at the invasive front of pancreatic 
tumors and possibly determine the metastatic phenotype of individual tumors (Hermann et 
al., 2007).  
However, several reports have shown that CD133- cells have properties of self-renewal. For 
example, the CD133- population in colon cancer cells was capable of self-renewal and 
tumorigenicity (Shmelkov et al., 2008). CD133- cells derived from several glioma patients 
were tumorigenic in nude rats and several of the resulting tumors contained CD133+ cells 
(Wang et al., 2008). Taken together, these data suggest that CD133 is not an appropriate 
marker for isolation of CSCs in some solid tumors. 
3.4 ATP-binding cassette sub-family B member 5 (ABCB5)  
Schatton et al. identified an ABCB5+ subpopulation of melanoma cells that showed a high 
capacity for re-establishing malignancy after xenotransplantation into mice (Schatton et al., 
2008). In addition, this group reported that systemic administration of monoclonal 
antibodies against ABCB5 induces antibody-dependent cell-mediated cytotoxicity in ABCB5+ 
malignant melanoma initiating cells and exerts tumor-inhibitory effects in a xenograft 
model. Quintana et al. showed that the frequency of CSCs in human melanoma might 
depend on the conditions of the xenotransplantation assay using NOD/SCID/IL2Rγcnull 
mice (Quintana et al., 2008). Further investigation is required to elucidate the phenotypic 
differences between tumorigenic and non-tumorigenic cell populations. 
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3.5 Integrin α6/CD49f 
Integrin α6 (CD49f) is expressed in the stem cells of several tissues including epidermal, 
keratinocyte, and mammary stem cells (Fortunel et al., 2003; Jones & Watt 1993; Li et al., 
1998). A small subpopulation of mouse mammary stem cells, sorted as CD45-/Ter119-
/CD31-/Sca-1low/CD24med/CD49fhigh, was used to purify a rare subset of adult mouse 
mammary stem cells that were able to individually regenerate an entire mammary gland in 
vivo (Stingl et al., 2006). 
Lathia et al. reported that CSCs in glioblastomas express high levels of integrin α6. In 
addition, targeting integrin α6 inhibits self-renewal, proliferation, and tumor formation, 
suggesting that it is a possible therapeutic target (Lathia et al., 2010). Another study showed 
that knockdown of α6-integrin causes mammosphere-derived cells to lose their ability to 
grow as mammospheres and abrogates their tumorigenicity in mice, suggesting that 
integrin α6 is a potential therapeutic target for breast cancer stem cells (Cariati et al., 2008). 
As described above, surface markers are very useful tools to isolate and enrich CSCs from a 
variety of cancer cells. However, expression of these markers is not adequate for the 
complete purification of CSCs. Moreover, there are currently no universal surface markers 
for a pure population of CSCs. Since surface markers are also expressed on normal stem 
cells and these normal stem cells may contaminate the CSC population, more specific 
markers need to be determined. 
4. Side population 
In contrast to cell-type specific surface markers, the use of Hoechst 33342 dye to identify and 
isolate CSCs as a side population (SP) overcomes the barrier of diverse phenotype markers 
and replaces it with more direct functional markers (Hadnagy et al., 2006).  
SP cells were identified in normal murine hematopoietic stem cells. The method is based on 
the efficient and specific efflux of the fluorescent DNA-binding dye Hoechst 33342 by an 
ATP-binding cassette (ABC) transporter. By monitoring the blue and red fluorescence 
emission of Hoechst 33342 following UV excitation, a very small subpopulation of cells was 
observed that displayed low blue and red fluorescence (Goodell et al, 1996).  
Kondo et al. were the first to report SP cells in rat C6 glioma cell line (Kondo et al., 2004). 
Because SP cells show resistance to anti-cancer drugs due to rapid efflux of those 
compounds and exhibit higher tumorigenicity than non-SP cells, the SP phenotype defines a 
type of CSC. Following this finding, SP cells have been identified in various established cell 
lines (Nakanishi et al., 2010) and tumor specimens (Hirschmann-Jax et al., 2004). 
Consistent with these data, we also detected SP cells in human MCF-7 breast cancer cells 
(Fig. 2). To determine the gate of the SP, it is important to use an ABC transporter-blocking 
agent such as verapamil or reserpine as a control. In the case of MCF-7 cells, reserpine was 
more effective than verapamil in inhibiting efflux of Hoechst 33342 by SP cells. In contrast to 
MCF-7 cells, SP cells have not been observed in human MDA-MB-231 breast cancer cells 
(data not shown). Therefore, SP cells might not be universal among cell lines. The SP 
technique could help to identify more specific CSC markers by comparing the expression 
profiles of SP and non-SP cells. 
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Fig. 2. Side population assay in human MCF-7 breast cancer cells MCF-7 cells were stained 
with Hoechst 33342 in the absence or presence of reserpine, an inhibitor of ABC transporter, 
and analyzed by flow cytometry 
SP cells are heterogeneous and vary according to tissue type, stage of development, and 
method of preparation (Uchida et al., 2004). Although SP cells are usually enriched in 
primitive stem cells, some reports suggest that SP cells do not distinguish stem cells (Triel et 
al., 2004). 
5. ALDEFLUOR assay 
Similar to the SP assay, the ALDEFLUOR dye has been developed as a direct functional 
marker of CSCs. The aldehyde dehydrogenase (ALDH) family of cytosolic isoenzymes is 
responsible for oxidizing intracellular aldehydes, leading to the oxidation of retinol to 
retinoic acid. Increased ALDH activity has been described in human hematopoietic stem 
cells (Hess et al., 2004). As few as 10 ALDEFLUOR-positive cells isolated from the rat 
hematopoietic system were capable of long-term repopulation of bone marrow upon 
transplantation in sub-lethally irradiated animals. 
ALDEFLUOR staining uses an ALDH substrate, BODIPY-aminoacetaldehyde (BAAA). 
BAAA is transported into living cells through passive diffusion and is converted into the 
reaction product BODIPY-aminoacetate (BAA-) by intracellular ALDH. BAA- is retained 
inside cells and becomes brightly fluorescent (Christ et al., 2007). A specific ALDH inhibitor, 
diethylaminobenzaldehyde (DEAB), is used to determine background fluorescence. Thus, 
the cells that have high ALDH activity can be detected in the green fluorescence channel by 
standard flow cytometry. As shown in Fig. 3, we have shown that both MCF-7 and MDA-
MB-231 cells contain ALDEFLUOR-positive cells. The proportion of ALDEFLUOR-positive 
cell was varied by fetal bovine serum (FBS) concentration (unpublished data).  
This method has been used to isolate CSCs from breast cancer cells as well as multiple 
myeloma and leukemia cells (Matsui et al., 2004; Pearce et al., 2005). CSCs with high ALDH 
activity have been shown to generate tumors in NOD/SCID mice with phenotypic 
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characteristics resembling the parental tumor (Ginestier et al., 2007). In addition, ALDH 
expression is associated with poor prognosis in breast cancer (Ginestier et al., 2007; Marcato 
et al., 2011). 
 
 
Fig. 3. ALDEFLUOR assay in human breast cancer cell lines MCF-7 and MDA-MB-231 cells 
were incubated with ALDEFLUOR substrate BAAA alone (left) or in the presence of the 
ALDH inhibitor DEAB (right), and then analyzed by flow cytometry. DEAB was used to 
establish the baseline fluorescence of these cells (shown in blue) and to define the 
ALDEFLUOR-positive region (shown in red) 
Although the ALDEFLUOR assay is a potential protocol for CSC isolation, there are several 
limitations of this technique in certain tumors. For example, both ALDEFLUORbr and 
ALDEFLUORlow cells from the H522 lung carcinoma cell line were able to initiate tumors 
after transplantation into NOD/SCID mice. Moreover, tumors generated from 
ALDEFLUORlow cells grew faster and were larger than the tumors from ALDEFLUORbr cells 
(Ucar et al., 2009). These results suggest that the ALDEFLUOR assay is not suitable for lung 
CSCs.  
Another problem is that the stem cell population identified using the ALDEFLUOR assay is 
presumably heterogeneous and must be dissected using additional surface markers. In 
breast cancer cell lines, cell selection using the CD44+/CD24-/ALDH+ phenotype increases 
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the tumorigenicity of breast cancer cells in comparison with CD44+/CD24- or ALDH+ cells 
(Ginestier et al., 2007). This suggests that CSCs obtained with a given marker can be further 
divided into distinct metastatic or non-metastatic subpopulations using additional markers. 
These data open new possibilities for cancer stem cell biology with therapeutic applications 
using marker combinations. 
6. CSCs in human cancer cell lines 
According to the CSC model, new cancer therapies should focus on targeting and 
eliminating CSCs, which requires the ability to characterize CSCs.  
Clinical CSC samples are difficult to obtain and expand in vitro. A large number of cells 
should be required for high-throughput screening of lead compounds or drug development. 
Our experience with breast cancer cells obtained from clinical tumors indicates that a 
common, distinctive feature of breast CSCs is currently not available. 
As described in the section 2, the capability to form non-adherent spheres has been 
recognized in cancer cell lines that have been established from different solid tumor types. 
In addition, CSCs isolated by several approaches from established cancer cell lines can be 
considered models of direct xenografts in immunodeficient mice. Compared with clinical 
CSCs, the CSCs in human cancer cell lines are easily accessible and provide a simple model 
for obtaining reproducible results.  
For example, we have found that a concentration of nicotine closely related to the blood 
concentration in cigarette smokers (10 nM–10 μM) increases a proportion of ALDH+ 
population in MCF-7 cells (Hirata et al, 2010). This population, which formed 
mammospheres, was characterized with respect to Notch signaling. Fillmore et al. reported 
that the estrogen/FGF/Tbx3 signaling axis has been shown to regulate CSC numbers both 
in vitro and in vivo by using a proportion of the CD44+/CD24−/ESA+ population in MCF-7 
cells (Fillmore et al., 2010). Curcumin, a phytochemical compound from the Indian spice 
turmeric, decreased the SP population in rat C6 glioma cells (Fong et al., 2010). Given that 
many human cancer cell lines have been used to test the functions of oncogenes and for anti-
cancer drug screening, CSCs in human cancer cell lines can serve as a good model for both 
drug discovery and elucidating the mechanism of disease. 
Various drug-screening platforms that were specifically designed to target CSCs have begun 
to identify novel anti-cancer drugs (Pollard et al., 2009; Gupta et al., 2009). RNA interference 
libraries also can be screened to identify factors that control CSC tumorigenicity (Wurdak et 
al., 2010). However, considerable effort should be made to assess the validity, optimal 
experimental conditions, and the genetic stability of the screening system (van Staveren et 
al., 2009).  
7. Self-renewal pathways of CSCs 
The CSC model provides therapeutic strategies beyond traditional anti-proliferative agents 
(Zhou et al., 2009). A potential approach to eliminating CSCs is blocking the essential self-
renewal signaling pathway for CSC survival. Since self-renewal is critical for both normal 
stem cells and CSCs, common self-renewal pathways presumably exist among them. In 
addition, these self-renewal pathways might be more conserved than surface markers 
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among CSCs. Taken together, these observations suggest that the search for drugs that 
target this common mechanism would be a powerful strategy for drug discovery. 
It has been suggested that specific signaling pathways such as Notch, Wnt/ǃ-catenin, and 
Hedgehog play a role in the self-renewal and differentiation of normal stem cells. 
Alterations in genes that encode signaling molecules belonging to these pathways have been 
found in human tumor samples (Lobo et al, 2007; Sánchez-García et al., 2007), suggesting 
that they are likely involved in CSC regulation (Fig. 4).  
 
Fig. 4. Self-renewal signaling pathways in CSCs. CSCs are thought to share many molecular 
similarities with normal stem cells 
7.1 Notch  
The Notch signaling pathway plays an important role in the maintenance of a variety of 
adult stem cells, including breast (Dontu et al., 2004), neural (Hitoshi et al., 2002) and 
intestinal (Fre et al., 2005) stem cells, by promoting self-renewal. 
Components of the Notch pathway reportedly act as oncogenes in a wide range of human 
tumors including breast cancers and gliomas (Kanamori et al., 2007; Reedijk et al., 2005; 
Stylianou et al., 2006). In addition, breast CSCs have been shown to exist within breast cell 
lines and primary samples and to self-renew via the Notch pathway (Harrison et al., 2010). 
Neurospheres derived from human glioblastoma specimens have been shown to grow via 
the Notch-dependent pathway (Fan et al., 2010). 
Ǆ-Secretase inhibitors, which inhibit cleavage of activated Notch receptors and thereby 
prevent Notch signaling, may be a promising approach for clinical trial. MK-0752 , one of Ǆ-
Secretase inhibitors, is currently undergoing clinical trials as a target for breast cancer stem 
cells after chemotherapy (ClinicalTrials.gov, number NCT00645333) and recurrent CNS 
malignancies (Fouladi et al., 2011). 
7.2 Wnt/β-catenin 
The Wnt/ǃ-catenin signaling pathway plays an important role in embryonic development 
(Clevers, 2006). This pathway is considered a master switch that controls proliferation 
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versus differentiation in both stem cell and cancer cell maintenance and growth in intestinal, 
epidermal, and hematopoietic tissues (Van der Wetering et al., 2002; Reya & Clevers, 2005). 
Wnt pathways are commonly hyperactivated in tumors and are required for sustained 
tumor growth (Reya & Clevers, 2005). 
Several small molecule inhibitors of Wnt/ǃ-catenin signaling have been developed. ICG-001 
selectively antagonizes interactions between ǃ-catenin and the cyclic AMP response 
element-binding protein (CBP), which is a transcriptional co-activator essential for ǃ-
catenin-mediated transcription (Emami et al., 2004). NSC668036 binds to the PDZ domain of 
the Wnt-pathway signaling molecule Disheveled and mimics the endogenous Wnt inhibitor 
Dapper1 (Zhang et al., 2006). XAV939 selectively inhibits ǃ-catenin-mediated transcription. 
This inhibitor stimulates ǃ-catenin degradation by stabilizing axin, which is a member of the 
destruction complex that induces ubiquitin-mediated degradation of ǃ-catenin (Huang et 
al., 2009). Among these Wnt inhibitors, an ICG-001 analog (known as PRI-721) is currently 
being tested in a clinical trial in patients with gastrointestinal cancers.  
7.3 Hedgehog  
The Hedgehog signaling pathway was initially identified in Drosophila as a mediator of 
segmental patterning during development (Nusslein-Volhard & Wieschaus, 1980). This 
pathway is also essential for maintaining the normal adult stem cell population (Ingham & 
McMahon, 2001).  
Xu et al. identified a Hedgehog-dependent subset of brain tumor stem cells (Xu et al., 2008). 
Inhibition of Hedgehog signaling has been shown to be effective in a pancreatic cancer 
xenograft model (Jimeno et al., 2009). Moreover, the Hedgehog pathway has also been 
implicated in maintaining human leukemic CSCs (Dierks et al., 2008; Zhao et al., 2009). Loss 
of smoothened, which is a Hedgehog pathway component, resulted in depletion of chronic 
myeloid CSCs.  
Based on these data, many inhibitors of this pathway are currently under development 
(Mahindroo et al., 2009). For example, GDC-0449 was originally identified as a smoothened 
antagonist in a chemical compound screen (Robarge et al., 2009) and has been used in a 
clinical trial in solid tumor patients (Von Hoff et al., 2009). BMS-833923 (XL139) was also 
used in a clinical trial for uncontrolled basal cell nevus syndrome (Siu et al., 2010). 
8. Conclusions 
CSCs play a central role in the field of cancer biology and evidence is accumulating that 
CSCs are involved in tumorigenesis and response to therapy. Although the contribution of 
CSCs to cancer development is still unclear, targeting CSCs is a potential approach for 
discovering new drugs that eliminate all cancer cells and finding effective and clinically 
applicable therapies that prevent disease recurrence and metastasis. 
CSC populations in established cancer cell lines are considered good in vitro models. These 
CSCs can be easily isolated with the protocols described herein and are useful for chemical 
screening. However, CSC isolation protocols and the efficiency of purification should be 
improved. The percentage of CSCs in cell lines, their capability to form tumors, and their 
self-renewal potential can widely vary. In addition, it is essential to investigate whether the 
www.intechopen.com
 Identification and Characterization of Cancer Stem Cells Using Flow Cytometry 
 
117 
CSCs identified in cancer cell lines have the same properties as the CSCs obtained from 
patient specimens. Future studies are required to evaluate CSC phenotypes. 
Development of new therapies for targeting CSCs must consider both the differences 
between CSCs and other tumor cells and the signaling pathways shared between CSCs and 
normal stem cells. Elucidation of the specific mechanisms by which CSCs regulate self-
renewal will be useful for the design of new therapeutic alternatives. CSC-targeted therapies 
should avoid or minimize the potential toxic side effects to normal tissue stem cells. 
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